Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Allan T, van Oosterom"'
Publikováno v:
Sarcoma, Vol 6, Iss 4, Pp 135-139 (2002)
We report the case of a 66-year-old man presenting with a high-grade pleomorphic sarcoma at the left elbow 16 years after the extravasation of adriamycin given for a malignant ifbrous histiocytoma of the tibia.We suggest that this sarcoma originated
Externí odkaz:
https://doaj.org/article/ce3a70d3e86041b69c250d3154a3434b
Autor:
H. Jan Keizer, Derek Crowther, Ole Steen Nielsen, Allan T. Van Oosterom, Javier Hornedo Muguiro, Christine Van Pottelberghe, Renier Somers, Thomas Tursz
Publikováno v:
Sarcoma, Vol 1, Iss 2, Pp 99-101 (1997)
Purpose. This study investigates the efficacy and toxicity of daily oral etoposide in chemotherapy for non-heavily pretreated advanced and metastatic soft tissue sarcoma (STS).
Externí odkaz:
https://doaj.org/article/0e73ffa9b99246b68b4408694ee6a1e8
Autor:
Patrick Schöffski, Scott M. Schuetze, S. McCoy, Binh Bui, Daniel E. Stepan, Jean-Yves Blay, Yu Nien Sun, Allan T. van Oosterom, Robert S. Benjamin, Lee S. Rosen, Jörg T. Hartmann, Laurence H. Baker, Peter Reichardt, Keith M. Skubitz, Justus Duyster
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3eb7029d7f7ce2df55c2d0e2e944b5
http://europepmc.org/articles/PMC3123696
http://europepmc.org/articles/PMC3123696
Autor:
Herlinde Dumez, Agnieszka Wozniak, Jose Jimeno, C Stefan, Pascal Wolter, Patrick Schöffski, Allan T. van Oosterom
Publikováno v:
Expert Opinion on Pharmacotherapy. 9:1609-1618
Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease progresses during or after chemotherapy with doxorubicin or ifosfamide have few options and very limited life expectancy. In this setting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f142ba044d01f74d8136833b8362fd6
https://doi.org/10.1517/14656566.9.9.1609
https://doi.org/10.1517/14656566.9.9.1609
Autor:
Michael Heinrich, Denis Soulières, Zariana Nikolova, Jonathan A. Fletcher, Stephan Dirnhofer, and Grant McArthur, Shane G. Supple, Ajia Town, John F. Seymour, Heikki Joensuu, Allan T. van Oosterom, George D. Demetri, Jane F. Apperley, Amy Harlow, Arin McKinley, Lilla Di Scala, Christopher L. Corless, Richard Herrmann
Publikováno v:
Clinical Cancer Research. 14:2717-2725
Purpose: To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases. Experimental Design: This was a phase II, open-label, single arm study. Patients ≥15 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::297cbcdd6be2cdd8a7e8f2dca5558372
https://doi.org/10.1158/1078-0432.ccr-07-4575
https://doi.org/10.1158/1078-0432.ccr-07-4575
Autor:
Ernst A. de Bruijn, Gunter Guetens, Allan T. van Oosterom, Marc Martens, Robert A. A. Maes, J. Selleslach, Rita Aerts, Herlinde Dumez, Gert De Boeck
Publikováno v:
Anti-Cancer Drugs. 18:211-218
Our objective was to determine the response to gemcitabine plus docetaxel in advanced urothelial transitional cell carcinoma in a phase II trial, and gemcitabine distribution between plasma and erythrocytes, following docetaxel administration. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e552895900c9fd03c72a6a7849d92696
https://doi.org/10.1097/cad.0b013e328010ee5c
https://doi.org/10.1097/cad.0b013e328010ee5c
Autor:
Janine Mansi, Ernst A. de Bruijn, Gunther Guetens, Robert A. A. Maes, G. Momerency, Hans Prenen, Allan T. van Oosterom, Peter Blake, Tim Mant, Peter Harper, Gert De Boeck, Diane Sawyers, M.S. Highley
Publikováno v:
Journal of Analytical Oncology. 4
Purpose : Ifosfamide can cause an unexplained encephalopathy. The incidence after intravenous infusion is 10%, but is much higher after oral administration. This study assesses the pharmacokinetics of oral ifosfamide in relation to neurotoxicity. Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13901df3abe4f42e1da4110be67acfb3
https://doi.org/10.6000/1927-7229.2015.04.01.3
https://doi.org/10.6000/1927-7229.2015.04.01.3
Autor:
Jean-Yves Blay, Rolf D. Issels, Peter Reichardt, Allan T. van Oosterom, Axel Le Cesne, Ian Judson, John Simes, Jaap Verweij, Martine Van Glabbeke, Paolo G. Casali
Publikováno v:
European Journal of Cancer. 42:2277-2285
The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc33089923b0fa2367a6e0d5b839e1c
https://doi.org/10.1016/j.ejca.2006.03.029
https://doi.org/10.1016/j.ejca.2006.03.029
Autor:
Sharyn D. Baker, Alex Sparreboom, Gunther Guetens, Allan T. van Oosterom, Ernst A. de Bruijn, Ron H.N. van Schaik, Susan E. Bates, Hans Prenen, Jaap Verweij, Kees Nooter, Erin R. Gardner, William D. Figg, Herman Burger, Floris A. de Jong
Publikováno v:
Clinical pharmacology and therapeutics
Clinical Pharmacology & Therapeutics, 80(2), 192-201. Wiley-Blackwell
Clinical Pharmacology & Therapeutics, 80(2), 192-201. Wiley-Blackwell
Objective: Our objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate–binding cassette transporters (ABCB1 and ABCG2) and enzymes (cytochrome P450 [CYP] 2C9,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3b236fc751970f545a2f2e675da96d
https://doi.org/10.1016/j.clpt.2006.05.003
https://doi.org/10.1016/j.clpt.2006.05.003
Autor:
Paolo G. Casali, Marcus Schlemmer, Anne Hagemeijer, Ian Judson, Martine Van Glabbeke, Allan T. van Oosterom, Michel Stul, Peter Hohenberger, John Zalcberg, Jaap Verweij, Raf Sciot, Serge Leyvraz, Axel Le Cesne, Maria Debiec-Rychter, Jean-Yves Blay
Publikováno v:
European Journal of Cancer. 42:1093-1103
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee9d4d8f45cd5256860657da1394736
https://doi.org/10.1016/j.ejca.2006.01.030
https://doi.org/10.1016/j.ejca.2006.01.030